Eric Whitman, MD, of Atlantic Health, and Gino K. In, MD, MPH, of USC Norris Comprehensive Cancer Center, open this OncLive My Treatment Approach program on matching immunotherapy to the patient in advanced cutaneous squamous cell carcinoma.
Back
My Treatment Approach: Matching Immunotherapy to the Patient in Advanced Cutaneous Squamous Cell Carcinoma
Eric Whitman, MD, and Gino K. In, MD, MPH, discuss how they select and sequence immunotherapy in advanced cutaneous squamous cell carcinoma, from high-risk resected disease through unresectable disease, using two patient cases to illustrate how comorbidities and transplant status shape treatment decisions.
My Treatment Approach: Matching Immunotherapy to the Patient in Advanced Cutaneous Squamous Cell Carcinoma
Episodes
All
All
Dr Whitman and Dr In discuss the FDA approval of adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma who have completed surgery and adjuvant radiation yet remain at elevated risk for recurrence.
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
2
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma
3
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL
4
Researchers Discover Immune 'Off Switch' Used by Cancer Cells
5